INC Research Offers Safety Considerations to Reduce Risk in Vulnerable Patient Populations at ACRP 2012 Global Conference
(Thomson Reuters ONE) -
VP of Early Phase to Address Ethical Principles and Strategies to Reduce
Vulnerability
Raleigh, N.C., April 12, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, will feature Pierre Geoffroy, PhD, Vice President, Early Phase
to discuss ethical principles related to vulnerable patient populations at the
ACRP 2012 Global Conference & Exhibition, April 14-17, 2012, at the George R.
Brown Convention Center in Houston, Texas. INC Research experts also will be
available for onsite meetings at booth #336 in the exhibition hall.
Vulnerable populations are defined by ethical frameworks as persons whose
ability to make independent decisions about trial participation free from undue
influence or coercion is either not possible or may be compromised, and
therefore, who need special protection. Normal healthy volunteers (NHVs) are
used in the conduct of many Phase I studies. However, since they will not
benefit from exposure to the test article and because most of these studies
require patients to stay in Phase I units for up to 28 days at a time, it is
common to pay these subjects for their participation. The issue of vulnerability
in this population needs special consideration.
In the panel discussion "Normal Healthy Volunteers as a Vulnerable Population:
Implications for Researchers" (SP115), Dr. Geoffroy and the other panelists will
discuss the ethical principles related to vulnerability, the vulnerability of
NHVs, and safety considerations to reduce risk in this population. Also covered
will be strategies that institutional review boards and research staff can
implement to reduce the vulnerability of this population. This session is part
of the Ethics & Human Subject Protection track, which will be held on April 16
from 8 to 10:15 a.m.
INC Research's early phase specialists are among the most highly respected
experts in their fields. Through the Company's center of research in Toronto,
Canada, the early phase team can develop an optimal early phase plan from
initial protocol design through to regulatory submission, providing support at
agency meetings and assistance to help present and explain complex data. Whether
it is a small biotechnology company requiring additional specialist input into
early phase program, or a large pharmaceutical company looking for nimble
problem-solving capabilities and personal interaction on a scientific and
operational level, INC Research has the flexibility to rapidly address a wide
range of needs.
To meet with INC Research at ACRP or for more information on our early phase or
other clinical development capabilities, please visit the website.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development
programs of the highest integrity. Pharmaceutical and biotechnology companies
look to INC Research for a complete range of customized Phase I through Phase IV
programs in all therapeutic areas and innovative pediatric and women's health
trials. The Company's Trusted Process(®) methodology and therapeutic foresight
lead customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at (at)inc_research.
CONTACT:
Lori Dorer, Media, (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1602151]
Unternehmensinformation / Kurzprofil:
Datum: 12.04.2012 - 20:59 Uhr
Sprache: Deutsch
News-ID 134659
Anzahl Zeichen: 4461
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 134 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Offers Safety Considerations to Reduce Risk in Vulnerable Patient Populations at ACRP 2012 Global Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
